On day 2 post-treatment with 15 μM (IC90) melphalan, wild-type TP53 XG7 myeloma cells presented a decreased BrdU incorporation and accumulated in the G2 phase (Figure S2A,B). The gene discussed is TP53; the disease is plasma cell myeloma.